Short Interest in VanEck Biotech ETF (NASDAQ:BBH) Expands By 33.3%

VanEck Biotech ETF (NASDAQ:BBH) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 800 shares, an increase of 33.3% from the October 31st total of 600 shares. Based on an average daily volume of 4,800 shares, the days-to-cover ratio is presently 0.2 days.

VanEck Biotech ETF Stock Performance

Shares of NASDAQ:BBH opened at $167.37 on Friday. VanEck Biotech ETF has a 52-week low of $150.62 and a 52-week high of $183.64. The business has a 50-day moving average price of $171.97 and a 200-day moving average price of $173.08.

Institutional Trading of VanEck Biotech ETF

Several institutional investors and hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC lifted its holdings in shares of VanEck Biotech ETF by 10,376,390.9% in the 3rd quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock valued at $202,475,000 after buying an additional 1,141,403 shares during the period. Jane Street Group LLC lifted its holdings in VanEck Biotech ETF by 401.7% in the third quarter. Jane Street Group LLC now owns 8,348 shares of the company’s stock valued at $1,481,000 after acquiring an additional 6,684 shares during the period. Atlas Capital Advisors LLC purchased a new stake in VanEck Biotech ETF in the 2nd quarter worth approximately $960,000. Northwestern Mutual Wealth Management Co. grew its stake in shares of VanEck Biotech ETF by 5.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock worth $4,096,000 after purchasing an additional 1,334 shares during the period. Finally, Hyman Charles D purchased a new position in shares of VanEck Biotech ETF during the 2nd quarter valued at approximately $202,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.